Paragon Care Limited · ASX:PGC
Paragon Care — Shareholder Meeting (November 2017)
19 slides from Paragon Care's shareholder meeting presentation, Nov 22, 2017
Slide 1: AGM Presentation
AGM Presentation 22 November 2017 | PGC.ASX
Slide 2: Agenda
Agenda A low-risk exposure to a rapidly growing health care company Company highlights FY17 Results Summary & Overview FY18 guidance and Seasonality Operational updates Vision and strategy Appendix: Corporate Overview Paragon Care Limited (ASX: PGC) 2|
Slide 3: Investment Highlights
Investment Highlights Paragon is one of the premier medical equipment, device and consumables suppliers on the ASX Platform economics, valuable distribution networks and a customer-centric business model all differentiate Paragon’s service offering Favourable macro tailwinds given the ageing populat
Slide 4: FY17 Results Summary
FY17 Results Summary Record FY17 full year results reflect another strong year of growth with positive outlook for FY18 Revenue Net profit after tax Operating cash flow $117.2m $10.2m $12.0m 2016: $93.4m up 25% 2016: $7.5m up 35% 2016: $7.8m up 54% Gross profit Earnings per share Cash balance $46.1m
Slide 5: FY17 Results Overview
FY17 Results Overview Record FY17 full year results driven by strong organic growth across all sectors Financial highlights Record full year results across all key metrics — Revenue up 25% to $117.2m, driven by strong organic growth and a full year of earnings capture from the FY16 acquisitions of W
Slide 6: Proven Execution
Proven Execution Paragon has an enviable track record of buying sensibly and integrating successfully, which has supported long-term growth and strong returns to shareholders Paragon’s management team has a proven track record acquiring and integrating 14 businesses over the last 8 years Acquisition
Slide 7: FY18 guidance
FY18 guidance Paragon is targeting strong growth in FY18 across all key metrics FY18 Revenue Guidance FY18 EBITDA Guidance $125m – $135m $18m – $19m The above guidance excludes any benefit from potential new acquisitions FY18 is likely to be impacted by seasonality more so than in previous years, wi
Slide 8: Seasonality in Financial Performance
Seasonality in Financial Performance As previously guided, Paragon continues to expect seasonality in revenue and EBITDA Revenue seasonality: first half v second half Customer procurement cycles drive seasonality in Paragon’s P&L Seasonal trends in procurement are well established in the 58% 58% 59%
Slide 9: Operational Updates
Operational Updates Paragon has a strategic plan underway to accelerate its next phase of growth 1 2 3 CEO Strong Organic Strengthened Transition Growth Sales Team 4 5 6 Midas Paragon Care M&A Commercialisation Servicing & Pipeline Technology Paragon Care Limited (ASX: PGC) 9|
Slide 10: CEO Transition
1 CEO Transition CEO transition designed to accelerate both organic and inorganic growth Andrew Just appointed as CEO, effective 22 January 2018 “I’m excited about joining Paragon at a 25 years’ global experience across Fortune 500 and ASX- time when the organic growth opportunity listed healthcare
Slide 11: Strong Organic Growth for FY18
2 Strong Organic Growth for FY18 Increasing returns across Paragon Care’s existing portfolio of products and services Aged care Service & Maintenance Growth Initiatives Paragon Care continues to Paragon Care’s various servicing In January 2018, Paragon Care benefit from increasing offerings have bee
Slide 12: Strengthened Sales Team
3 Strengthened Sales Team Paragon continues to invest in a highly skilled sales team to drive growth Sales team by geography Paragon has a diverse and growing sales representation with a 55 strong sales team spread across Australia and New Zealand. Sales team is supported by 25 member customer QLD s
Slide 13: Midas Commercialisation
4 Midas Commercialisation Paragon’s eHealth offering – commercialisation edging closer Sales Pipeline for Midas MIDAS Software Solutions provides Paragon a pathway to the Midas is making strong in-roads in the sector with a number of exciting and fast-growing eHealth sector where we can deliver exci
Slide 14: Paragon Care Service & Technology
5 Paragon Care Service & Technology Paragon has merged all its service offerings into one national brand and initiative Outlook for Service & Technology Provide client focused service, support and Service and Maintenance contracts continue to gain traction technology management to the medical, scien
Slide 15: M&A Pipeline
6 M&A Pipeline M&A pipeline and opportunities are more exciting today than at any time in Paragon’s history Strong pipeline of value accretive M&A opportunities across three broad categories 1 2 3 Select additions to Additions to Service & Geographical Expansion product platform Maintenance offering
Slide 16: Clear Vision
Clear Vision Paragon’s vision is to be Australia’s leading supplier of medical equipment, devices and consumables Strategy Unique selling Target revenue proposition Strategy $250m Aspirational target driven by strong double digit To create a healthcare platform Highly fragmented industry, organic gr
Slide 17: Thank You
Thank You DISCLAIMER Some of the statements in this presentation constitute “forward-looking statements” that do not directly or exclusively relate to historical facts. These forward-looking statements reflect Paragon Care Limited’s current intentions, plans, expectations, assumptions and beliefs ab
Slide 18: Appendix: Corporate overview
Appendix: Corporate overview Paragon Care Limited (ASX: PGC) 18 |
Slide 19: Corporate overview
Corporate overview Highly aligned Board and management team with a supportive long-term shareholder base Financial Information Board of Directors Share price (20-Nov-17) $0.855 Shane Tanner Mark Simari Number of shares (m) 166.2 Non-Executive Chairman Managing Director / Chief Executive Officer Chai